Ängelholm, Sweden, June 4, 2024 – Airsonett, a leading Swedish MedTech company, has announced significant findings from an independent technical study evaluating its Temperature-controlled Laminar Airflow (TLA) technology.
The study was presented at the EAACI Congress in Valencia, Spain, on May 31st. It demonstrates the significant efficacy of Airsonett's TLA technology in reducing airborne allergens such as cat dander, grass pollen, and house dust mite allergens in the breathing zone. The treatment is intended for patients suffering from allergic diseases such as asthma and atopic dermatitis.
Key Findings
• Particle Reduction: A mean reduction rate of between 99.95 % to 99.99 % for particles sized between 0.5 µm to 10 µm
• Cat Allergen (Fel d 1): Mean reduction rate: 99.95 % (from 39.96 ng/m³ to below 0.043 ng/m³)
• House Dust Mite Allergen (Der p 1): Mean reduction rate: 99.97 % (from 28.62 ng/m³ to below 0.337 ng/m³)
• Grass Pollen Allergen (Phl p 5): Mean reduction rate: 99.997 % (from 62.21 ng/m³ to below 0.423 ng/m³)
The results show a remarkable reduction in allergen levels, with the concentration of allergens in the breathing zone falling below detectable limits.
The study further strengthens earlier technical studies on particle removal. Previous studies on the effects of TLA have shown that reducing allergens and particles during sleep effectively enhances the quality of life and sleep for patients with allergic diseases, reduces asthma attacks (exacerbations), and improves asthma control. The treatment is also cost-efficient compared to pharmacological add-on treatment alternatives.
Statement from Airsonett's CEO:
"We are delighted with the results of this study, which confirms the efficacy of our TLA technology in significantly reducing airborne allergens in the breathing zone. The results are particularly impressive, considering that other allergen avoidance methods have been studied, but they have not shown similar results," said Anders Due-Boje, CEO of Airsonett.
About the study
The study, conducted by ALYATEC Clinical Research Center in Strasbourg, France, assessed TLA's capacity to purify the breathing zone by testing it against controlled concentrations of common allergens. Read the study here. See https://airsonett.eu/clinical-data/ for clinical data.
For more information:
Anders Due-Boje, CEO, Airsonett AB
E-mail: anders.due-boje@airsonett.eu
Phone: +46 70 526 03 00
About the TLA treatment
TLA Treatment is given at home with the medical device Airsonett Air4. The technology creates a zone of at least 99.95 percent clean air, free of allergens and particles, around the patient's breathing area during sleep or rest. When the biological stress decreases during the night, the immune system and airways can rest and the patient gains better resistance to allergens also during the day.
TLA treatment is clinically proven effective. The treatment is prescribed by the healthcare system in Sweden and is the most prescribed treatment for patients with severe allergic asthma. The treatment is included in the national Swedish guidelines for asthma and in the Euforea Asthma Pocket Guide. Airsonett is currently launching the TLA treatment in selected markets in Europe.
Airsonett® is a Swedish medical device company that leads the way in the development of non-pharmacologic treatment of allergic severe asthma and eczema. Airsonett® Air4 is a non-invasive device for treatment in the home, based on the patented Temperature-controlled Laminar Airflow technology (TLA). Treatment with the Airsonett Air4 significantly reduces allergens and other airborne irritants from the patient’s breathing zone during rest and sleep. Airsonett Air4 is a CE-marked class 1 medical device intended to be used for the alleviation of symptoms of allergy-induced diseases such as allergic asthma and eczema. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health-economic studies. Airsonett Air4 holds a 510(k) cleared class II approval from FDA. The company’s main shareholders are SEB Venture Capital, Industrifonden, Magnus Lundberg and Fåhraeus Startup and Growth. For more information visit https://airsonett.eu/.
Powered by Notified